Ficerafusp alfa efficacy and safety
3 evidence topics · 19 sources
Summary: phase 1b efficacy by cohort and data cut
All efficacy results for ficerafusp alfa plus pembrolizumab come from BCA101X1101 (NCT04429542), an open-label, nonrandomized, single-arm phase 1/1b trial in which response was investigator-assessed per RECIST v1.1. No randomized result has been reported; the FORTIFI-HN01 interim analysis is expected in mid-2027.
In the first-line 1500 mg weekly expansion cohort reported by Hanna et al. (2026), with a data snapshot of 20 March 2025, 42 participants received at least one dose and 39 were evaluable for efficacy (28 HPV-negative, 11 HPV-positive); median follow-up was 26.3 months. In the HPV-negative subgroup, the confirmed objective response rate (ORR) was 54% (15 of 28; 95% CI, 34 to 73), including six participants (21%) with complete response, and the clinical benefit rate was 86% (24 participants). Median duration of response was 21.7 months (95% CI, 6.0 to not estimable), median time to response 1.4 months, median progression-free survival (PFS) 9.9 months (95% CI, 4.4 to 22.7), and median overall survival (OS) 21.3 months (95% CI, 9.9 to not estimable); an OS assessment in April 2025 gave a 24-month OS rate of 46% (95% CI, 23 to 65). Confirmed ORRs were 54% with a combined positive score (CPS) of 1-19 (n = 13) and 53% with CPS ≥20 (n = 15). In the HPV-positive subgroup, the confirmed ORR was 27% (3 of 11), median PFS 2.0 months, and median OS 16.4 months. An earlier abstract of the same cohort (data cut 16 December 2024) reported an ORR of 64% (18 of 28) in HPV-negative participants and 54% (21 of 39) overall.
At the 31 March 2026 data cut, an integrated analysis of three HPV-negative cohorts reported, for 750 mg weekly (30 evaluable), 1500 mg weekly (28 evaluable), and 2000 mg every 2 weeks with pembrolizumab 400 mg every 6 weeks (27 evaluable), respectively: confirmed ORRs of 57% (95% CI, 37%-74%), 54% (34%-72%), and 48% (29%-68%); complete response rates of 13%, 25%, and 30%; deep response (≥80% tumor shrinkage) in 47% (8 of 17), 80% (12 of 15), and 77% (10 of 13) of responders; and median PFS of 6.9 (4.6-NE), 9.9 (4.4-22.7), and 12.7 (4.9-NE) months. Median follow-up was 20, 36, and 24 months. In the 1500 mg cohort, median OS was 21.3 months (95% CI, 9.9-33.6) and the 3-year OS rate was 31%; OS was “Not mature” in the other two cohorts. Earlier cuts of the other cohorts reported an ORR of 57% (17 of 30) with a complete response rate of 10% (3 of 30) at 750 mg (9 July 2025), and a confirmed ORR of 48% (13 of 27) with a complete response rate of 26% (7 of 27) at 2000 mg every 2 weeks (16 December 2025). In a post hoc pooled analysis at the March 2026 cut, deep response was associated with longer PFS than partial response with <80% shrinkage (covariate-adjusted hazard ratio 0.35; 95% CI, 0.15-0.91).
Hanna et al. compare the HPV-negative ORR of 54% with “the ORR of 19% with pembrolizumab monotherapy in patients with CPS ≥1 in the KEYNOTE-048 phase III trial”, stating the caveats of cross-trial comparison; no head-to-head study has been conducted. In the dose-escalation combination arm (head and neck or anal canal squamous cell carcinoma, any number of prior lines), four of 13 evaluable participants (31%) had a confirmed response.
Summary: phase 1b safety
In the 1500 mg weekly cohort (data snapshot 20 March 2025; 42 participants), treatment-related adverse events (TRAEs) of any grade occurred in 40 participants (95%), grade 3 TRAEs in 19 (45%), and a grade 4 TRAE (pericarditis) in one (2%); no fatal TRAEs were reported. Acneiform dermatitis occurred in 32 participants (76%) and reached grade 3 in five (12%); dermatologic TRAEs of any grade occurred in 36 (86%), with grade 3 events in eight (19%). Investigators gave topical steroids and antibiotics, and no participant discontinued treatment because of dermatitis acneiform or rash TRAEs. Anemia TRAEs occurred in 15 participants (36%), grade 3 in six (14%), and bleeding-related TRAEs in 14 (33%), grade 3 in one (2%). TRAEs led to interruption of ficerafusp alfa in 20 participants (48%) and to its discontinuation in five (12%). Grade ≥3 treatment-emergent adverse events occurred in 33 participants (79%), and treatment-emergent adverse events led to death in three (7%). Patient-reported outcomes were not assessed.
At the 31 March 2026 cut of the three HPV-negative cohorts (750 mg weekly, n = 31; 1500 mg weekly, n = 30; 2000 mg every 2 weeks, n = 30), grade 3 TRAEs occurred in 11 (35%), 15 (50%), and 16 (53%) participants; acneiform dermatitis in 27 (87%), 23 (77%), and 24 (80%); and grade 3 anemia in 3 (10%), 7 (23%), and 8 (27%). Ficerafusp alfa-related treatment-emergent adverse events led to discontinuation in 2 (6%), 3 (10%), and 2 (7%) participants. One participant had grade 4 hypokalemia and one grade 4 pericarditis, and no participant had a grade 5 event related to ficerafusp alfa. In the 15-participant dose-escalation combination arm, acneiform dermatitis occurred in 11 (73%), and no grade 4 TRAEs or treatment-related deaths were observed.
Summary: FORTIFI-HN01 and FORTIFI-FLEX design and status
FORTIFI-HN01 (NCT06788990) is a multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial with a planned enrollment of about 650 participants at 231 locations. The phase 2 portion randomized participants 1:1:1 to ficerafusp alfa 1500 mg weekly, ficerafusp alfa 750 mg weekly, or placebo, each with pembrolizumab 200 mg every 3 weeks. Bicara announced 1500 mg weekly as the phase 3 dose in January 2026 and completed the transition to phase 3 in February 2026; participants in the 750 mg arm crossed over to 1500 mg. The phase 3 portion randomizes participants 2:1 to ficerafusp alfa 1500 mg weekly or placebo, each with pembrolizumab (up to 35 cycles), stratified by PD-L1 CPS (1-19 vs ≥20) and disease extent. The primary endpoints are ORR per RECIST 1.1 by blinded independent central review (BICR) at an interim analysis and OS at the final analysis. The registry gives a study start of 2025-01-28 and an estimated primary completion of 2028-04. In November 2026 Bicara reported enrollment sufficient for an interim analysis in mid-2027 and stated a potential U.S. launch in 2028.
The registry inclusion criteria are age ≥18 years; recurrent or metastatic squamous cell carcinoma of the oral cavity, hypopharynx, larynx, or oropharynx, “with documented HPV-negative disease if presenting with OPSCC” (nasopharynx and paranasal sinus primaries excluded); PD-L1 CPS ≥1; no prior systemic therapy in the recurrent or metastatic setting, with systemic therapy given as part of multimodal treatment allowed if completed more than 6 months earlier; measurable disease per RECIST 1.1; and ECOG performance status 0 or 1. Exclusions include progression within 6 months of curative-intent systemic therapy, prior anti-TGFβ therapy, prior anti-EGFR antibody (except radiosensitizing and multimodal treatment for locoregionally advanced disease), immune checkpoint inhibitor therapy completed within 6 months, and active major bleeding or a major bleeding episode within 4 weeks. HPV testing applies to oropharyngeal tumors only; Bicara states that testing for HPV status is “typically only being conducted in tumors originating from the oropharynx”.
The sources differ on the biomarker and assessment criteria:
- HPV status: the EU trial record requires HPV-negative documentation “per central testing” for oropharyngeal tumors and names Qiagen Manchester Limited for development of an HPV DNA assay; both trial-in-progress abstracts state that HPV status of oropharyngeal tumors is confirmed by central laboratory testing; the ClinicalTrials.gov record states documented HPV-negative disease without naming a testing site or method.
- PD-L1: the ClinicalTrials.gov record states “PD-L1 CPS ≥1” without an assay; the EU record specifies 22C3 immunohistochemistry, with central testing when local documentation is not available.
- Measurable disease: the EU record and the 2025 trial-in-progress abstract require measurable disease assessed by BICR; the ClinicalTrials.gov record and the 2026 abstract state measurable disease per RECIST 1.1 without naming the assessor.
- Prior anti-EGFR therapy: the ClinicalTrials.gov record and the 2026 poster except radiosensitizing and multimodal treatment; the quoted EU exclusion reads “Prior therapy with an anti-EGFR antibody.”
- Bleeding and life expectancy: the EU record and the 2026 poster also exclude participants with a known bleeding diathesis, and the EU record also excludes participants with “rapidly progressing disease in the treating investigator's opinion.”
- In the phase 1b 1500 mg weekly cohort, PD-L1 CPS was assessed locally with 22C3 “or other validated assay”, and oropharyngeal tumors required a p16 immunohistochemistry or HPV molecular test result; oral cavity, hypopharynx, and larynx tumors were considered HPV-negative.
FORTIFI-FLEX (NCT07807163) is a multicenter, open-label, randomized phase 2 trial. All participants receive ficerafusp alfa 1500 mg weekly with pembrolizumab 200 mg every 3 weeks for a 12-week loading phase; participants without progression are then randomized 2:1 to ficerafusp alfa 2250 mg every 3 weeks or continued 1500 mg weekly, each with pembrolizumab 200 mg every 3 weeks. The primary endpoint is the proportion of maintenance-phase participants who are progression-free by BICR per RECIST 1.1 and alive, at approximately 9 months. Estimated enrollment is 160 in the registry and “(n=150-200)” in the corporate presentation. Bicara announced initiation in August 2026; the registry lists an estimated start of 2026-09, 7 locations, and estimated primary completion of 2028-03. Eligibility follows FORTIFI-HN01, except that the EU record requires oropharyngeal HPV-negative status “as determined by a validated test”, accepts 22C3 PD-L1 CPS ≥1 “determined locally or centrally”, and refers to progression after “curative intent platinum-containing systemic therapy”. Bicara expects results by the time of a potential U.S. approval. No results have been reported.